Loading...

Hemispherx Biopharma

DB:HXB1
Snowflake Description

Limited growth and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HXB1
DB
$9M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
  • Hemispherx Biopharma has significant price volatility in the past 3 months.
HXB1 Share Price and Events
7 Day Returns
-5.8%
DB:HXB1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-60.6%
DB:HXB1
-10.2%
DE Biotechs
-6%
DE Market
HXB1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hemispherx Biopharma (HXB1) -5.8% -17.6% -42% -60.6% -92.5% -96.2%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • HXB1 underperformed the Biotechs industry which returned -10.2% over the past year.
  • HXB1 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
HXB1
Industry
5yr Volatility vs Market
Related Companies

HXB1 Value

 Is Hemispherx Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Hemispherx Biopharma. This is due to cash flow or dividend data being unavailable. The share price is €0.098.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hemispherx Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hemispherx Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HXB1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.22
AMEX:HEB Share Price ** AMEX (2019-04-18) in USD $0.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hemispherx Biopharma.

DB:HXB1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:HEB Share Price ÷ EPS (both in USD)

= 0.14 ÷ -0.22

-0.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hemispherx Biopharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Hemispherx Biopharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Hemispherx Biopharma's expected growth come at a high price?
Raw Data
DB:HXB1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-13.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Hemispherx Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Hemispherx Biopharma's assets?
Raw Data
DB:HXB1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.11
AMEX:HEB Share Price * AMEX (2019-04-18) in USD $0.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:HXB1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:HEB Share Price ÷ Book Value per Share (both in USD)

= 0.14 ÷ 0.11

1.33x

* Primary Listing of Hemispherx Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hemispherx Biopharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Hemispherx Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Hemispherx Biopharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HXB1 Future Performance

 How is Hemispherx Biopharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hemispherx Biopharma expected to grow at an attractive rate?
  • Unable to compare Hemispherx Biopharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Hemispherx Biopharma's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Hemispherx Biopharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:HXB1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:HXB1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -13.2%
DB:HXB1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 23.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HXB1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HXB1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 1 -11 -13 1
2019-12-31 1 -5 -12 1
DB:HXB1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -11 -10
2018-09-30 0 -9 -10
2018-06-30 0 -8 -8
2018-03-31 0 -7 -8
2017-12-31 0 -8 -8
2017-09-30 0 -9 -7
2017-06-30 0 -10 -9
2017-03-31 0 -9 -8
2016-12-31 0 -7 -8
2016-09-30 0 -9 -9
2016-06-30 0 -9 -10
2016-03-31 0 -13 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Hemispherx Biopharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Hemispherx Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HXB1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Hemispherx Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HXB1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.20 -0.20 -0.20 1.00
2019-12-31 -0.20 -0.20 -0.20 1.00
DB:HXB1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.22
2018-09-30 -0.25
2018-06-30 -0.23
2018-03-31 -0.26
2017-12-31 -0.29
2017-09-30 -0.28
2017-06-30 -0.37
2017-03-31 -0.35
2016-12-31 -0.34
2016-09-30 -0.45
2016-06-30 -0.50
2016-03-31 -0.68

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Hemispherx Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Hemispherx Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hemispherx Biopharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HXB1 Past Performance

  How has Hemispherx Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hemispherx Biopharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hemispherx Biopharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Hemispherx Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Hemispherx Biopharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Hemispherx Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hemispherx Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HXB1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.37 -9.81 6.20 4.74
2018-09-30 0.18 -10.20 6.30 4.60
2018-06-30 0.23 -8.37 6.59 3.79
2018-03-31 0.41 -8.15 6.47 3.56
2017-12-31 0.44 -8.26 6.57 4.09
2017-09-30 0.40 -7.44 6.80 5.01
2017-06-30 0.34 -9.05 6.03 5.57
2017-03-31 0.14 -8.16 6.05 5.36
2016-12-31 0.09 -7.50 6.83 4.97
2016-09-30 0.10 -9.47 6.42 3.99
2016-06-30 0.10 -10.41 7.32 4.61
2016-03-31 0.14 -13.95 7.68 6.15
2015-12-31 0.13 -15.23 7.15 7.82
2015-09-30 0.15 -16.55 7.45 9.07
2015-06-30 0.17 -16.95 7.94 9.00
2015-03-31 0.16 -17.06 8.43 8.89
2014-12-31 0.20 -17.45 9.06 8.54
2014-09-30 0.19 -16.19 8.97 7.91
2014-06-30 0.18 -17.12 8.87 8.19
2014-03-31 0.18 -16.45 8.19 8.17
2013-12-31 0.15 -16.23 7.72 8.18
2013-09-30 0.17 -18.49 9.75 10.55
2013-06-30 0.17 -19.94 9.34 10.74
2013-03-31 0.18 -18.66 9.26 10.15
2012-12-31 0.21 -17.35 9.06 9.48
2012-09-30 0.20 -15.01 7.07 7.32
2012-06-30 0.20 -11.16 7.05 6.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Hemispherx Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Hemispherx Biopharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Hemispherx Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Hemispherx Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hemispherx Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HXB1 Health

 How is Hemispherx Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hemispherx Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hemispherx Biopharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Hemispherx Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hemispherx Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hemispherx Biopharma Company Filings, last reported 3 months ago.

DB:HXB1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.17 5.93 1.83
2018-09-30 6.44 5.95 4.08
2018-06-30 9.10 2.61 4.24
2018-03-31 10.20 2.66 4.64
2017-12-31 8.70 1.84 2.11
2017-09-30 10.04 1.47 2.30
2017-06-30 10.33 0.52 3.21
2017-03-31 12.95 0.00 3.75
2016-12-31 15.50 0.00 5.87
2016-09-30 16.63 0.00 8.01
2016-06-30 17.49 0.00 6.51
2016-03-31 18.41 0.00 7.85
2015-12-31 20.37 0.00 8.91
2015-09-30 23.17 0.00 12.38
2015-06-30 26.76 0.01 15.71
2015-03-31 26.97 0.02 17.01
2014-12-31 25.00 0.02 16.11
2014-09-30 26.37 0.03 17.43
2014-06-30 29.37 0.04 20.21
2014-03-31 31.99 0.05 21.55
2013-12-31 29.30 0.06 18.19
2013-09-30 32.15 7.12 15.15
2013-06-30 36.14 7.12 18.15
2013-03-31 41.38 7.14 23.00
2012-12-31 44.70 7.15 29.45
2012-09-30 36.61 5.87 25.06
2012-06-30 33.54 4.46 21.61
  • Hemispherx Biopharma's level of debt (114.5%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.2% vs 114.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Hemispherx Biopharma has less than a year of cash runway based on current free cash flow.
  • Hemispherx Biopharma has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.6% each year.
X
Financial health checks
We assess Hemispherx Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Hemispherx Biopharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HXB1 Dividends

 What is Hemispherx Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Hemispherx Biopharma dividends.
If you bought €2,000 of Hemispherx Biopharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Hemispherx Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hemispherx Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HXB1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:HXB1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Hemispherx Biopharma has not reported any payouts.
  • Unable to verify if Hemispherx Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Hemispherx Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Hemispherx Biopharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Hemispherx Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hemispherx Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Hemispherx Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HXB1 Management

 What is the CEO of Hemispherx Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Equels
COMPENSATION $987,223
AGE 65
TENURE AS CEO 3.2 years
CEO Bio

Mr. Thomas K. Equels, Esq. M.S., J.D. has been the Chief Executive Officer of Hemispherx Biopharma, Inc. since February 25, 2016 and its President since August 13, 2015. Mr. Equels has been an Executive Vice Chairman at Hemispherx Biopharma, Inc. since 2008 and served as its Secretary since January April 2009. He serves as Litigation Counsel of Hemispherx Biopharma Inc., in a number of complex cases over ten years. He was owner of the Equels Law Firm. He served as the President and Managing Director of Equels Law Firm. He served as the Chief Financial Officer of Hemispherx Biopharma, Inc. since December 4, 2013 until February 19, 2015. He served as General Counsel of Hemispherx Biopharma, Inc. from January 1, 2010 to October 1, 2016. He served as Managing Director of Holtzman Equels P.A. For more than 25 years, he has represented national and state governments, banks, insurance companies, aviation companies, construction and development companies. Mr. Equels has extensive experience in international matters and served as counsel for the Republic of Panama, Chinese National Petroleum Corp. and worked extensively in Europe as well as in South America, Asia and Africa. He served as a Co-General Counsel of Hemispherx Biopharma, Inc from May 15, 2009 to January 1, 2010. He has been a Director at Hemispherx Biopharma, Inc. since November 28, 2008. He is a Member of the Florida Bar Association, the American Bar Association and the Academy of Florida Trial Lawyers. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree in Management from Troy University.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Hemispherx Biopharma management team in years:

3.2
Average Tenure
67
Average Age
  • The tenure for the Hemispherx Biopharma management team is about average.
Management Team

Thomas Equels

TITLE
Executive Vice Chairman
COMPENSATION
$987K
AGE
65
TENURE
3.2 yrs

Adam Pascale

TITLE
CFO & Chief Accounting Officer
COMPENSATION
$295K
AGE
70
TENURE
3.2 yrs

Peter Rodino

TITLE
Executive Director of Governmental Relations
COMPENSATION
$399K
AGE
67
TENURE
2.5 yrs

Wayne Springate

TITLE
Senior Vice President of Operations
COMPENSATION
$344K
AGE
47
TENURE
7.9 yrs

David Strayer

TITLE
Chief Scientific Officer & Medical Director
COMPENSATION
$329K
AGE
72
TENURE
3.2 yrs

Ann Marie Coverly

TITLE
Director of Administration & Human Resources and Investor Relations Manager
TENURE
6.3 yrs

Carol Smith

TITLE
Chief Manufacturing Officer & Deputy Chief Scientific Officer
COMPENSATION
$171K
AGE
67
TENURE
26.3 yrs

Ralph Cavalli

TITLE
Vice President of QC & Manufacturing
COMPENSATION
$244K
AGE
60
TENURE
9 yrs

Joseph Horvath

TITLE
Deputy Chief Medical Officer
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Hemispherx Biopharma board of directors in years:

3.2
Average Tenure
64.5
Average Age
  • The tenure for the Hemispherx Biopharma board of directors is about average.
Board of Directors

William Mitchell

TITLE
Chairman of the Board & Chairman of Scientific Advisory Board
COMPENSATION
$182K
AGE
83
TENURE
3.2 yrs

Thomas Equels

TITLE
Executive Vice Chairman
COMPENSATION
$987K
AGE
65
TENURE
11.3 yrs

Stewart Appelrouth

TITLE
Director
COMPENSATION
$182K
AGE
64
TENURE
2.7 yrs

Ronald H. Brus

TITLE
Member of Scientific Advisory Board
AGE
55

W. Burnette

TITLE
Member of Scientific Advisory Board

Christopher Nicodemus

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Hemispherx Biopharma insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Mar 19 Buy Thomas Equels Individual 19. Mar 19 19. Mar 19 13,400 €0.15 €2,072
03. Dec 18 Buy Thomas Equels Individual 30. Nov 18 30. Nov 18 20,000 €0.17 €3,396
06. Nov 18 Buy Stewart Appelrouth Individual 05. Nov 18 05. Nov 18 25,238 €0.19 €4,869
29. Oct 18 Buy Thomas Equels Individual 26. Oct 18 26. Oct 18 3,500 €0.18 €624
25. Oct 18 Buy Thomas Equels Individual 25. Oct 18 25. Oct 18 100,000 €0.18 €17,586
27. Jul 18 Buy Thomas Equels Individual 27. Jul 18 27. Jul 18 34,483 €0.25 €8,582
24. Jul 18 Buy Stewart Appelrouth Individual 24. Jul 18 24. Jul 18 126,000 €0.27 €33,404
23. Jul 18 Buy Thomas Equels Individual 23. Jul 18 23. Jul 18 112,904 €0.26 €29,908
23. Jul 18 Buy Wayne Springate Individual 23. Jul 18 23. Jul 18 32,259 €0.26 €8,545
23. Jul 18 Buy Adam Pascale Individual 23. Jul 18 23. Jul 18 32,259 €0.26 €8,545
30. Apr 18 Buy Stewart Appelrouth Individual 27. Apr 18 27. Apr 18 100,000 €0.26 €26,435
30. Apr 18 Buy Thomas Equels Individual 27. Apr 18 27. Apr 18 32,000 €0.26 €8,459
X
Management checks
We assess Hemispherx Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Hemispherx Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HXB1 News

Simply Wall St News

HXB1 Company Info

Description

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Details
Name: Hemispherx Biopharma, Inc.
HXB1
Exchange: DB
Founded: 1990
$8,285,828
64,425,318
Website: http://www.hemispherx.net
Address: Hemispherx Biopharma, Inc.
860 North Orange Avenue,
Suite B,
Orlando,
Florida, 32801,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX HEB Common Shares NYSE MKT LLC US USD 12. Jul 1996
DB HXB1 Common Shares Deutsche Boerse AG DE EUR 12. Jul 1996
LSE 0J4H Common Shares London Stock Exchange GB USD 12. Jul 1996
Number of employees
Current staff
Staff numbers
32
Hemispherx Biopharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:40
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.